​

AN2 Therapeutics Stock (NASDAQ:ANTX)

ForecastRevenueOwnershipFinancialsChart
AN2 Therapeutics by TradingView

Previous Close

$1.27

52W Range

$0.87 - $22.22

50D Avg

$1.21

200D Avg

$1.89

Market Cap

$37.65M

Avg Vol (3M)

$492.52K

Beta

-0.22

Div Yield

-

ANTX Company Profile

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

41

IPO Date

Mar 25, 2022

Website

ANTX Performance

ANTX Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-69.64M$-42.26M$-21.57M
Net Income$-64.73M$-41.47M$-21.47M
EBITDA$-69.64M$-42.26M$-21.57M
Basic EPS-$-2.70$-1.18
Diluted EPS-$-2.70$-1.18

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
AVTEAerovate Therapeutics, Inc.
PMVPPMV Pharmaceuticals, Inc.
MLYSMineralys Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
MNOVMediciNova, Inc.
RZLTRezolute, Inc.
PEPGPepGen Inc.
ANEBAnebulo Pharmaceuticals, Inc.
PHVSPharvaris N.V.
ADAGAdagene Inc.
MOLNMolecular Partners AG